811
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Aromatase Inhibitor-Associated Musculoskeletal Pain: Taking ‘Aim‘ at a Symptom in Breast Cancer Survivors

Pages 191-193 | Published online: 05 May 2011

Bibliography

  • Partridge AH : Non-adherence to endocrine therapy for breast cancer.Ann. Oncol.17(2) , 183–184 (2006).
  • Burstein HJ , PrestrudAA, SeidenfeldJ et al.: American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.J. Clin. Oncol.28(23) , 3784–3796 (2010).
  • Henry NL , GilesJT, StearnsV: Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.Oncology (Williston Park)22(12) , 1401–1408 (2008).
  • Henry NL , GilesJT, AngD et al.: Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.Breast Cancer Res. Treat.111(2) , 365–372 (2008).
  • Clauw DJ : Fibromyalgia: an overview.Am. J. Med.122(12 Suppl. 1) , S3–S13 (2009).
  • Henry NL , BanerjeeM, BlossomD et al.: Duloxetine for treatment of aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS). Presented at: 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8–12 December 2010.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.